Search
                    Diffuse Large B-Cell Lymphoma Clinical Trials
A listing of 33  Diffuse Large B-Cell Lymphoma  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 33
        
                There are currently 33 active clinical trials seeking participants for Diffuse Large B-Cell Lymphoma research studies. The states with the highest number of trials for Diffuse Large B-Cell Lymphoma participants are California, Ohio, New York and Texas.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
                                
            
            
        Recruiting
                            
            
                This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/25/2025
            
            Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio         
        
        
            Conditions: Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
        
            
        
    
                
                                    Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
                                
            
            
        Recruiting
                            
            
                This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called Bruton Tyrosine Kinase in order to stop cancer growth. R-CHOP is the acronym for the combination of five drugs: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. It is the most widely used chemoimmunother...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/11/2025
            
            Locations: Cleveland Clinic, Cleveland, Ohio  +2 locations         
        
        
            Conditions: Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
        
            
        
    
                
                                    Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
                                
            
            
        Recruiting
                            
            
                This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/19/2025
            
            Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey  +6 locations         
        
        
            Conditions: B-ALL, DLBCL, B ALL, Dlbcl-Ci, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, Diffuse Large B-cell Lymphoma, HGBL, HGBL, Nos
        
            
        
    
                
                                    A Long-term Extension Study of PCI-32765 (Ibrutinib)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/15/2025
            
            Locations: City of Hope Cancer Center, Duarte, California  +173 locations         
        
        
            Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
        
            
        
    
                
                                    Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
                                
            
            
        Recruiting
                            
            
                B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy.
ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 150 adult...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/15/2025
            
            Locations: University of California Los Angeles /ID# 246357, Los Angeles, California  +33 locations         
        
        
            Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
        
            
        
    
                
                                    A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/14/2025
            
            Locations: The University of Arizona Cancer Center - North Campus ( Site 0124), Tucson, Arizona  +198 locations         
        
        
            Conditions: Diffuse Large B-Cell Lymphoma
        
            
        
    
                
                                    A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers. The effects are studied in adult participants with certain types of lymphomas or solid tumors that are advanced or metastatic (spread to other parts of the body).
The study has three parts:
* Part A will test PF-08046032 alone at increasing dose levels in participants with certain lymp...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/14/2025
            
            Locations: Highlands Oncology Group, PA, Fayetteville, Arkansas  +8 locations         
        
        
            Conditions: Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer
        
            
        
    
                
                                    A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
                                
            
            
        Recruiting
                            
            
                B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL)...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/12/2025
            
            Locations: University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona  +17 locations         
        
        
            Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
        
            
        
    
                
                                    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
                                
            
            
        Recruiting
                            
            
                Background:
B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR).
Objective:
To study the safety of ViPOR for people with B-cell lymphoma.
Eligibility:
People ages 18 and older with B-cell lymphoma whose cancer has returned or not improved af...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/09/2025
            
            Locations: National Institutes of Health Clinical Center, Bethesda, Maryland         
        
        
            Conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
        
            
        
    
                
                                    A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
                                
            
            
        Recruiting
                            
            
                The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/08/2025
            
            Locations: Alaska Oncology & Hematology, LLC, Anchorage, Alaska  +33 locations         
        
        
            Conditions: Diffuse Large B-Cell Lymphoma
        
            
        
    
                
                                    Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).             
        
        
    Gender:
                ALL
            Ages:
                Between 3 years and 31 years
            Trial Updated:
                08/07/2025
            
            Locations: New York Medical College, Valhalla, New York         
        
        
            Conditions: Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
        
            
        
    
                
                                    A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
                                
            
            
        Recruiting
                            
            
                B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed.
Epcoritamab is an investigational drug being...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/04/2025
            
            Locations: City of Hope National Medical Center /ID# 273338, Duarte, California  +152 locations         
        
        
            Conditions: Diffuse Large B-Cell Lymphoma
        
            
        
    1 - 12 of 33
            